Anna C. Ferrari

Montefiore Medical Center — United States

Medicine · Health Sciences

27h-index7.7kcitations92works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(68), Immunotherapy and Immune Responses(17), Cancer, Lipids, and Metabolism(17), Cancer Immunotherapy and Biomarkers(15), Prostate Cancer Diagnosis and Treatment(10)

Publications92 total

Phase II Randomized Study of MK‐2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG‐ACRIN E2809)
The Prostate·2026Open Access
Data from Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
2023Open Access
Supplemental Figure 1 from Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
2023Open Access
Supplemental Figure 2 from Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
2023Open Access
Supplementary Data from Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
2023Open Access
Data from Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data from Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
2023Open Access
Supplemental Figure 2 from Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
2023Open Access
Supplemental Figure 1 from Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
2023Open Access
Data from Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
2023Open Access
Supplemental Figure 3 from Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
2023Open Access
Supplemental Figure 3 from Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
2023Open Access
Supplementary Data from Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
2023Open Access
Supplementary Data from Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
2023Open Access
Data from Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
2023Open Access
A phase III double blinded study of early intervention after radical prostatectomy with androgen deprivation therapy with darolutamide versus placebo in men at highest risk of prostate cancer metastasis by genomic stratification (ERADICATE).
Journal of Clinical Oncology·2022· 3 cited
Exploring Spatial-Temporal Changes in <sup>18</sup>F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide
Journal of Clinical Oncology·2020· 26 citedOpen Access
Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Clinical Cancer Research·2020· 58 citedOpen Access
Genomic profiling of prostate cancer at a diverse academic center.
Journal of Clinical Oncology·2020· 1 cited
Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer
Cancer Medicine·2020· 31 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Alejandro Gómez-Pinillos(9), Robert E. Gallagher(6), Liliana Ossowski(4), Mark N. Stein(4), Nelson N. Stone(4), Glenn Liu(4), Isaac Yi Kim(4), Celestia S. Higano(3), David I. Quinn(3), Jonathan Melamed(3), Ralf Kurek(3), Long G. Wang(3), Pamela D. Unger(3), Richard G. Stock(3), Andrew J. Armstrong(3), Philip W. Kantoff(2), Anne Keating(2), Johann S. de Bono(2), George F. Atweh(2), Xiaomei Liu(2)